# DENTSPLY SIRONA Inc.: financial statements, quarterly

XRAY · Nasdaq · CIK 818479 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xray.md) · [Financials](/companies/xray/financials.md) · [Filings](/companies/xray/filings.md) · [Insiders](/companies/xray/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xray/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [947](/filings/0000818479-24-000093.md) | [1,012 d](/filings/0000818479-26-000075.md) | [953](/filings/0000818479-25-000056.md) | [984](/filings/0000818479-25-000155.md) | [951](/filings/0000818479-25-000257.md) | [905 d](/filings/0000818479-26-000075.md) | [879](/filings/0000818479-26-000149.md) | [936](/filings/0000818479-26-000255.md) | [904](/filings/0000818479-25-000257.md) | [961 d](/filings/0000818479-26-000075.md) | [880](/filings/0000818479-26-000149.md) | [898](/filings/0000818479-26-000255.md) |
| Cost of revenue | $m | [452](/filings/0000818479-24-000093.md) | [490 d](/filings/0000818479-26-000075.md) | [447](/filings/0000818479-25-000056.md) | [473](/filings/0000818479-25-000155.md) | [456](/filings/0000818479-25-000257.md) | [459 d](/filings/0000818479-26-000075.md) | [413](/filings/0000818479-26-000149.md) | [446](/filings/0000818479-26-000255.md) | [463](/filings/0000818479-25-000257.md) | [518 d](/filings/0000818479-26-000075.md) | [453](/filings/0000818479-26-000149.md) | [405](/filings/0000818479-26-000255.md) |
| Gross profit | $m | [495](/filings/0000818479-24-000093.md) | [522 d](/filings/0000818479-26-000075.md) | [506](/filings/0000818479-25-000056.md) | [511](/filings/0000818479-25-000155.md) | [495](/filings/0000818479-25-000257.md) | [446 d](/filings/0000818479-26-000075.md) | [466](/filings/0000818479-26-000149.md) | [490](/filings/0000818479-26-000255.md) | [441](/filings/0000818479-25-000257.md) | [443 d](/filings/0000818479-26-000075.md) | [427](/filings/0000818479-26-000149.md) | [493](/filings/0000818479-26-000255.md) |
| Research and development | $m | [46.0](/filings/0000818479-24-000093.md) | [43.0 d](/filings/0000818479-26-000075.md) | [42.0](/filings/0000818479-25-000056.md) | [41.0](/filings/0000818479-25-000155.md) | [40.0](/filings/0000818479-25-000257.md) | [42.0 d](/filings/0000818479-26-000075.md) | [36.0](/filings/0000818479-26-000149.md) | [37.0](/filings/0000818479-26-000255.md) | [37.0](/filings/0000818479-25-000257.md) | [40.0 d](/filings/0000818479-26-000075.md) | [44.0](/filings/0000818479-26-000149.md) | [45.0](/filings/0000818479-26-000255.md) |
| Selling, general and administrative | $m | [372](/filings/0000818479-24-000093.md) | [409 d](/filings/0000818479-26-000075.md) | [415](/filings/0000818479-25-000056.md) | [399](/filings/0000818479-25-000155.md) | [390](/filings/0000818479-25-000257.md) | [401 d](/filings/0000818479-26-000075.md) | [358](/filings/0000818479-26-000149.md) | [342](/filings/0000818479-26-000255.md) | [355](/filings/0000818479-25-000257.md) | [383 d](/filings/0000818479-26-000075.md) | [351](/filings/0000818479-26-000149.md) | [364](/filings/0000818479-26-000255.md) |
| Operating income | $m | [(236)](/filings/0000818479-24-000093.md) | [73.0 d](/filings/0000818479-26-000075.md) | [42.0](/filings/0000818479-25-000056.md) | [50.0](/filings/0000818479-25-000155.md) | [(462)](/filings/0000818479-25-000257.md) | [(509) d](/filings/0000818479-26-000075.md) | [63.0](/filings/0000818479-26-000149.md) | [(128)](/filings/0000818479-26-000255.md) | [(218)](/filings/0000818479-25-000257.md) | [(139) d](/filings/0000818479-26-000075.md) | [(35.0)](/filings/0000818479-26-000149.md) | [82.0](/filings/0000818479-26-000255.md) |
| Interest expense | $m | [18.0](/filings/0000818479-23-000084.md) | [23.0 d](/filings/0000818479-24-000021.md) | [18.0](/filings/0000818479-24-000036.md) | [17.0](/filings/0000818479-25-000155.md) | [18.0](/filings/0000818479-25-000257.md) | [16.0 d](/filings/0000818479-26-000075.md) | [19.0](/filings/0000818479-26-000149.md) | [24.0](/filings/0000818479-26-000255.md) | [23.0](/filings/0000818479-25-000257.md) | [22.0 d](/filings/0000818479-26-000075.md) | [24.0](/filings/0000818479-26-000149.md) | [22.0](/filings/0000818479-26-000255.md) |
| Income tax | $m | [16.0](/filings/0000818479-24-000093.md) | [(15.0) d](/filings/0000818479-26-000075.md) | [14.0](/filings/0000818479-25-000056.md) | [38.0](/filings/0000818479-25-000155.md) | [17.0](/filings/0000818479-25-000257.md) | [(95.0) d](/filings/0000818479-26-000075.md) | [25.0](/filings/0000818479-26-000149.md) | [(109)](/filings/0000818479-26-000255.md) | [198](/filings/0000818479-25-000257.md) | [(2.0) d](/filings/0000818479-26-000075.md) | [(32.0)](/filings/0000818479-26-000149.md) | [36.0](/filings/0000818479-26-000255.md) |
| Net income | $m | [(266)](/filings/0000818479-24-000093.md) | [67.0 d](/filings/0000818479-26-000075.md) | [18.0](/filings/0000818479-25-000056.md) | [(4.0)](/filings/0000818479-25-000155.md) | [(494)](/filings/0000818479-25-000257.md) | [(430) d](/filings/0000818479-26-000075.md) | [20.0](/filings/0000818479-26-000149.md) | [(45.0)](/filings/0000818479-26-000255.md) | [(427)](/filings/0000818479-25-000257.md) | [(146) d](/filings/0000818479-26-000075.md) | [(10.0)](/filings/0000818479-26-000149.md) | [37.0](/filings/0000818479-26-000255.md) |
| Diluted EPS | $ per share | [(1.25)](/filings/0000818479-24-000093.md) | not reported | [0.09](/filings/0000818479-25-000056.md) | [(0.02)](/filings/0000818479-25-000155.md) | [(2.46)](/filings/0000818479-25-000257.md) | not reported | [0.10](/filings/0000818479-26-000149.md) | [(0.22)](/filings/0000818479-26-000255.md) | [(2.14)](/filings/0000818479-25-000257.md) | not reported | [(0.05)](/filings/0000818479-26-000149.md) | [0.18](/filings/0000818479-26-000255.md) |
| Basic EPS | $ per share | [(1.25)](/filings/0000818479-24-000093.md) | not reported | [0.09](/filings/0000818479-25-000056.md) | [(0.02)](/filings/0000818479-25-000155.md) | [(2.46)](/filings/0000818479-25-000257.md) | not reported | [0.10](/filings/0000818479-26-000149.md) | [(0.22)](/filings/0000818479-26-000255.md) | [(2.14)](/filings/0000818479-25-000257.md) | not reported | [(0.05)](/filings/0000818479-26-000149.md) | [0.18](/filings/0000818479-26-000255.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [309](/filings/0000818479-23-000084.md) | [334](/filings/0000818479-25-000035.md) | [291](/filings/0000818479-24-000036.md) | [279](/filings/0000818479-24-000069.md) | [296](/filings/0000818479-24-000093.md) | [272](/filings/0000818479-26-000075.md) | [398](/filings/0000818479-25-000056.md) | [359](/filings/0000818479-25-000155.md) | [363](/filings/0000818479-25-000257.md) | [326](/filings/0000818479-26-000255.md) | [190](/filings/0000818479-26-000149.md) | [239](/filings/0000818479-26-000255.md) |
| Current assets | $m | [1,913](/filings/0000818479-23-000084.md) | [1,973](/filings/0000818479-25-000035.md) | [1,902](/filings/0000818479-24-000036.md) | [1,758](/filings/0000818479-24-000069.md) | [1,921](/filings/0000818479-24-000093.md) | [1,746](/filings/0000818479-26-000075.md) | [1,978](/filings/0000818479-25-000056.md) | [1,966](/filings/0000818479-25-000155.md) | [2,072](/filings/0000818479-25-000257.md) | [2,023](/filings/0000818479-26-000255.md) | [1,845](/filings/0000818479-26-000149.md) | [1,928](/filings/0000818479-26-000255.md) |
| Total assets | $m | [7,201](/filings/0000818479-23-000084.md) | [7,370](/filings/0000818479-25-000035.md) | [7,123](/filings/0000818479-24-000036.md) | [6,897](/filings/0000818479-24-000069.md) | [6,626](/filings/0000818479-24-000093.md) | [5,753](/filings/0000818479-26-000075.md) | [6,050](/filings/0000818479-25-000056.md) | [6,069](/filings/0000818479-25-000155.md) | [5,653](/filings/0000818479-25-000257.md) | [5,429](/filings/0000818479-26-000255.md) | [5,229](/filings/0000818479-26-000149.md) | [5,204](/filings/0000818479-26-000255.md) |
| Current liabilities | $m | [1,218](/filings/0000818479-23-000084.md) | [1,425](/filings/0000818479-25-000035.md) | [1,330](/filings/0000818479-24-000036.md) | [1,323](/filings/0000818479-24-000069.md) | [1,542](/filings/0000818479-24-000093.md) | [1,589](/filings/0000818479-26-000075.md) | [1,793](/filings/0000818479-25-000056.md) | [1,166](/filings/0000818479-25-000155.md) | [1,405](/filings/0000818479-25-000257.md) | [1,343](/filings/0000818479-26-000255.md) | [1,207](/filings/0000818479-26-000149.md) | [1,185](/filings/0000818479-26-000255.md) |
| Total liabilities | $m | [3,830](/filings/0000818479-23-000084.md) | [4,076](/filings/0000818479-25-000035.md) | [3,865](/filings/0000818479-24-000036.md) | [3,833](/filings/0000818479-24-000069.md) | [4,136](/filings/0000818479-24-000093.md) | [3,810](/filings/0000818479-26-000075.md) | [4,040](/filings/0000818479-25-000056.md) | [4,108](/filings/0000818479-25-000155.md) | [4,175](/filings/0000818479-25-000257.md) | [4,089](/filings/0000818479-26-000255.md) | [3,910](/filings/0000818479-26-000149.md) | [3,853](/filings/0000818479-26-000255.md) |
| Long-term debt | $m | [1,803](/filings/0000818479-23-000084.md) | [1,796](/filings/0000818479-25-000035.md) | [1,747](/filings/0000818479-24-000036.md) | [1,737](/filings/0000818479-24-000069.md) | [1,795](/filings/0000818479-24-000093.md) | [1,586](/filings/0000818479-26-000075.md) | [1,593](/filings/0000818479-25-000056.md) | [2,218](/filings/0000818479-25-000155.md) | [2,017](/filings/0000818479-25-000257.md) | [2,015](/filings/0000818479-26-000255.md) | [2,006](/filings/0000818479-26-000149.md) | [1,996](/filings/0000818479-26-000255.md) |
| Current portion of debt | $m | [187](/filings/0000818479-23-000084.md) | [77.0](/filings/0000818479-25-000035.md) | [343](/filings/0000818479-24-000036.md) | [362](/filings/0000818479-24-000069.md) | [422](/filings/0000818479-24-000093.md) | [128](/filings/0000818479-26-000075.md) | [742](/filings/0000818479-25-000056.md) | [184](/filings/0000818479-25-000155.md) | [378](/filings/0000818479-25-000257.md) | [228](/filings/0000818479-26-000075.md) | [230](/filings/0000818479-26-000149.md) | [228](/filings/0000818479-26-000255.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [3,375](/filings/0000818479-23-000084.md) | [3,293](/filings/0000818479-25-000035.md) | [3,258](/filings/0000818479-24-000036.md) | [3,064](/filings/0000818479-24-000069.md) | [2,491](/filings/0000818479-24-000093.md) | [1,942](/filings/0000818479-26-000075.md) | [2,010](/filings/0000818479-25-000056.md) | [1,960](/filings/0000818479-25-000155.md) | [1,478](/filings/0000818479-25-000257.md) | [1,339](/filings/0000818479-26-000255.md) | [1,318](/filings/0000818479-26-000149.md) | [1,351](/filings/0000818479-26-000255.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent, us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [134 d](/filings/0000818479-24-000093.md) | [160 d](/filings/0000818479-26-000075.md) | [25.0](/filings/0000818479-25-000056.md) | [208 d](/filings/0000818479-25-000155.md) | [141 d](/filings/0000818479-25-000257.md) | [87.0 d](/filings/0000818479-26-000075.md) | [7.0](/filings/0000818479-26-000149.md) | [48.0 d](/filings/0000818479-26-000255.md) | [79.0 d](/filings/0000818479-25-000257.md) | [101 d](/filings/0000818479-26-000075.md) | [40.0](/filings/0000818479-26-000149.md) | [99.0 d](/filings/0000818479-26-000255.md) |
| Capital expenditure | $m | [37.0 d](/filings/0000818479-24-000093.md) | [40.0 d](/filings/0000818479-26-000075.md) | [34.0](/filings/0000818479-25-000056.md) | [52.0 d](/filings/0000818479-25-000155.md) | [43.0 d](/filings/0000818479-25-000257.md) | [51.0 d](/filings/0000818479-26-000075.md) | [19.0](/filings/0000818479-26-000149.md) | [32.0 d](/filings/0000818479-26-000255.md) | [39.0 d](/filings/0000818479-25-000257.md) | [41.0 d](/filings/0000818479-26-000075.md) | [52.0](/filings/0000818479-26-000149.md) | [44.0 d](/filings/0000818479-26-000255.md) |
| Dividends paid | $m | [29.0 d](/filings/0000818479-24-000093.md) | [30.0 d](/filings/0000818479-26-000075.md) | [29.0](/filings/0000818479-25-000056.md) | [33.0 d](/filings/0000818479-25-000155.md) | [33.0 d](/filings/0000818479-25-000257.md) | [31.0 d](/filings/0000818479-26-000075.md) | [32.0](/filings/0000818479-26-000149.md) | [32.0 d](/filings/0000818479-26-000255.md) | [32.0 d](/filings/0000818479-25-000257.md) | [32.0 d](/filings/0000818479-26-000075.md) | [32.0](/filings/0000818479-26-000149.md) | [0.0 d](/filings/0000818479-26-000255.md) |
| Share repurchases | $m | [0.0 d](/filings/0000818479-24-000093.md) | [150 d](/filings/0000818479-26-000075.md) | [0.0](/filings/0000818479-24-000036.md) | [150 d](/filings/0000818479-25-000155.md) | [100 d](/filings/0000818479-25-000257.md) | [0.0 d](/filings/0000818479-26-000075.md) | not reported | not reported | [0.0 d](/filings/0000818479-25-000257.md) | [0.0 d](/filings/0000818479-26-000075.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [215](/filings/0000818479-23-000084.md) | [215](/filings/0000818479-24-000036.md) | [213](/filings/0000818479-24-000069.md) | [212](/filings/0000818479-24-000093.md) | [209](/filings/0000818479-25-000056.md) | [206](/filings/0000818479-25-000155.md) | [201](/filings/0000818479-25-000257.md) | [200](/filings/0000818479-26-000149.md) | [199](/filings/0000818479-26-000255.md) | [200](/filings/0000818479-25-000257.md) | [200](/filings/0000818479-26-000149.md) | [201](/filings/0000818479-26-000255.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 199,353,876 at 2026-07-24, from the cover of the [10-Q filed 2026-08-06](/filings/0000818479-26-000255.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.